Characterisation of T cell receptor repertoire in non-small cell lung cancer patients treated with immunotherapy

Abstract from the 2022 World Conference on Lung Cancer 6-9 August 2022, Vienna, Austria.-- EP16.01-033.Non-small cell lung cancer (NSCLC) therapy has experienced important changes in survival benefit and durable anti-tumor responses due to immune checkpoint blockers (ICBs). However, ICBs show some major limitations including low response rate and drug resistance in unselected patients. Despite the development of new predictive biomarkers, such as PD-L1 expression, microsatellite instability (MSI), or tumor mutation burden (TMB), there is an urgent need for biomarkers that identify which patients will benefit more from ICBs and define the reasons for failure of the treatment. Analysis of peripheral blood T cell receptor beta chain (TCR-β) repertoire and other serum biomarkers may provide information about the immune response in ICBs treated NSCLC patients.Peer reviewe